You are here: Stats bulletin home > Index of tables and graphics
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Tables
General population surveys of drug use (GPS)
Table GPS-0. Nationwide surveys among the general population: bibliographic references
Table GPS-1. Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population
Table GPS-1 part (i). Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population. Lifetime prevalence all adults (percentage)
Table GPS-1 part (ii). Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population. Survey methods
Table GPS-2. Lifetime prevalence of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-3. Last year prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population
Table GPS-4. Last year prevalence of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-5. Last month prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population
Table GPS-6. Last month prevalence of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-7. Last month prevalence and frequency of use of cannabis among all adults (15 to 64 years old) and young adults (15 to 34 years old) in nationwide surveys among the general population
Table GPS-7 part (i). Last month prevalence and frequency of use of cannabis among all adults (15 to 64 years old) and young adults (15 to 34 years old) in nationwide surveys among the general population. Last month prevalence (percentage)
Table GPS-7 part (ii). Last month prevalence and frequency of use of cannabis among all adults (15 to 64 years old) and young adults (15 to 34 years old) in nationwide surveys among the general population. Frequency of use among all users in last month (percentage)
Table GPS-8. Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population
Table GPS-8 part (i). Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population. Lifetime prevalence all adults (percentage): last survey available for each Member State
Table GPS-8 part (ii). Lifetime prevalence of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population. Survey methods: last survey available for each Member State
Table GPS-9. Lifetime prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-10. Last year prevalence (percentage) of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-11. Last year prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-12. Last month prevalence (percentage) of drug use among all adults (15 to 64 years old) in nationwide surveys among the general population: last survey available for each Member State
Table GPS-13. Last month prevalence (percentage) of drug use among young adults (15 to 34 years old) in nationwide surveys among the general population: last survey available for each Member State
Studies of youth and the schools population (EYE)
Table EYE-0. School surveys: sources
Table EYE-1. Recent school surveys: lifetime prevalence (percentage) of psychoactive substance use among students 15 to 16 years old
Table EYE-2. Recent school surveys: prevalence of cannabis use among students 15 to 16 years old
Table EYE-2 part (i). Recent school surveys: prevalence of cannabis use among students 15 to 16 years old. Percent lifetime prevalence (LTP), last year prevalence (LYP), and last month prevalence (LMP)
Table EYE-2 part (ii). Recent school surveys: prevalence of cannabis use among students 15 to 16 years old. Use patterns (percentages)
Table EYE-3. Recent school surveys: lifetime prevalence of psychoactive substance use and last month prevalence (LMP) of cannabis (percentages), among students 17 to 18 years old
Studies of the problematic drug use population (PDU)
Table PDU-0. Prevalence of problem drug use at national and local level: bibliographic references
Table PDU-1. Prevalence of problem drug use at national level and range in local estimates, 1999 to 2003: summary table (rate per 1000 aged 15 to 64).
Table PDU-1 part (i). Prevalence of problem drug use at national level and range in local estimates, 1999 to 2003: summary table (rate per 1000 aged 15 to 64). Problem drug use
Table PDU-1 part (ii). Prevalence of problem drug use at national level and range in local estimates, 1999 to 2003: summary table (rate per 1000 aged 15 to 64). Injecting drug use
Studies of drug users in prison (DUP)
Table DUP-0. Prevalence of drug use among prisoners: sources and bibliographic references
Table DUP-1. Prevalence of lifetime use of various drugs among prisoners
Table DUP-2. Prevalence of lifetime injecting drug use among prisoners
Table DUP-3. Prevalence of drug use within prison among prisoners
Table DUP-4. Prevalence of injecting drug use within prison among prisoners
Drug-related infections diseases (INF)
Table INF-0. Bibliographic references
Table INF-0 part (i). Bibliographic references: prevalence data
Table INF-0 part (ii). Bibliographic references: notifications data
Table INF-1. Prevalence of HIV infection among injecting drug users in the EU: summary table
Table INF-2. Prevalence of HCV infection among injecting drug users in the EU: summary table
Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU: summary table
Drug-related deaths (DRD)
Table DRD-0. Drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 2003: sources and bibliographic references
Table DRD-1. Summary of characteristics of the deceased in drug-related deaths according to national definitions
Table DRD-1 part (i). Summary of characteristics of the deceased in drug-related deaths according to national definitions. 2003 or last year with available information (demographic characteristics)
Table DRD-1 part (ii). Summary of characteristics of the deceased in drug-related deaths according to national definitions. 2003 or last year with available information (toxicology and population rates)
Table DRD-1 part (iii). Summary of characteristics of the deceased in drug-related deaths according to national definitions. 1990 or closest year with available information
Table DRD-2. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 1985 to 2003. Total drug-related deaths 1985 to 2003
Table DRD-2 part (i). Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 1985 to 2003. Total drug-related deaths 1985 to 2003: EU-15 Member States
Table DRD-2 part (ii). Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 1985 to 2003. Total drug-related deaths 1985 to 2003: New Member States
Table DRD-2 part (iii). Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 1985 to 2003. Male drug-related deaths 1990 to 2003
Table DRD-2 part (iv). Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 1985 to 2003. Female drug-related deaths 1990 to 2003
Table DRD-2 part (v). Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to national definitions, 1985 to 2003. Total drug-related deaths under the age of 25 years old (1990 to 2003). EU-15 Member States
Table DRD-3. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to EMCDDA standard definition 'Selection B', 1990 to 2003
Table DRD-4. Number of acute drug-related deaths recorded in EU Member States (25 members and candidates) according to EMCDDA standard definition 'Selection D', 1990 to 2003
Drug law offences (DLO)
Table DLO-1. Number of reports for drug law offences
Table DLO-1 part (i). Number of reports for drug law offences, 1995 to 2003
Table DLO-1 part (ii). Number of reports for drug law offences, 1985 to 2003
Table DLO-2. Offence type most involved in the report for drug law offences
Table DLO-3. Drug types involved in reports for drug law offences: percentage of all reports for drug law offences
Table DLO-4. Percentage of total drug law offences that are related to drug use or possession for use, 1996 to 2003
Table DLO-5. Cannabis-related offences: percentage among total drug law offences, 1996 to 2003
Table DLO-6. Heroin-related offences: percentage among total drug law offences, 1996 to 2003
Table DLO-7. Cocaine-related offences: percentage among total drug law offences, 1996 to 2003
Demand for treatment for drug use (TDI)
Table TDI-1. Sources for data on clients entering treatment in 2003
Table TDI-2. Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2003
Table TDI-2 part (i). Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2003. Total numbers of new clients entering treatment
Table TDI-2 part (ii). Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2003. Total numbers of all clients entering treatment
Table TDI-2 part (iii). Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2003. Numbers of treatment units covered for reporting clients entering treatment
Table TDI-2 part (iv). Numbers of clients entering treatment and numbers of reporting treatment centres, 1996 to 2003. Types of units covered for reporting clients entering treatment
Table TDI-3. Distribution by primary drug used of new clients entering treatment, 1993 to 2003
Table TDI-3 part (i). Distribution by primary drug used of new clients entering treatment, 1993 to 2003. Percentage of new clients using heroin
Table TDI-3 part (ii). Distribution by primary drug used of new clients entering treatment, 1993 to 2003. Percentage of new clients using cocaine
Table TDI-3 part (iii). Distribution by primary drug used of new clients entering treatment, 1993 to 2003. Percentage of new clients using cannabis
Table TDI-3 part (iv). Distribution by primary drug used of new clients entering treatment, 1993 to 2003. Percentage of new clients using stimulants
Table TDI-4. Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available.
Table TDI-4 part (i). Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Demographics and injecting status
Table TDI-4 part (ii). Characteristics of new clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Primary drug type used (percentage of new clients using) and of those, the percentage injecting it
Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available.
Table TDI-5 part (i). Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Demographics and injecting status of all clients entering treatment
Table TDI-5 part (ii). Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Primary drug type used by clients (percent of all clients) and of those, the percentage injecting it.
Table TDI-5 part (iii). Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Demographics and injecting status of all men entering treatment
Table TDI-5 part (iv). Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Demographics and injecting status of all women entering treatment
Table TDI-5 part (v). Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Primary drug type used by male clients (percentage of all male clients)
Table TDI-5 part (vi). Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2003 or most recent year available. Primary drug type used by female clients (percentage of all female clients)
Table TDI-6. Trends in gender distribution among new clients entering treatment from 1992 to 2003 (expressed as males / females ratio)
Table TDI-7. Incidence of treatment demands for drug use: new clients entering treatment in 2003 (rate per 100000 population)
Table TDI-8. Number of cases covered by the treatment demand indicator schedule reports: new clients and all clients entering treatment in 2003, by type of treatment centre
Table TDI-9. Clients entering outpatient treatment: mean age and gender distribution among new and all clients in 2003
Table TDI-10. New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data
Table TDI-10 part (i). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Age distribution (row percentage) for each primary drug type: summary
Table TDI-10 part (ii). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Distribution of primary drug used (column percentage) in each age group: summary
Table TDI-10 part (iii). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using opiates as primary drug
Table TDI-10 part (iv). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using cocaine as primary drug
Table TDI-10 part (v). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using stimulants as primary drug
Table TDI-10 part (vi). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using hallucinogens as primary drug
Table TDI-10 part (vii). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using hypnotics as primary drug
Table TDI-10 part (viii). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using volatile inhalants as primary drug
Table TDI-10 part (ix). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using cannabis as primary drug
Table TDI-10 part (x). New clients entering outpatient treatment: age and primary drug at treatment in 2003 for those countries supplying data. Number of clients using other drugs as primary drugs
Table TDI-11. New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data.
Table TDI-11 part (i). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Distribution of age at first use (row percentage) for each primary drug type: summary
Table TDI-11 part (ii). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Distribution of primary drug used (column percentages) in each age group: summary
Table TDI-11 part (iii). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using opiates as primary drug
Table TDI-11 part (iv). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using cocaine as primary drug
Table TDI-11 part (v). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using stimulants as primary drug
Table TDI-11 part (vi). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using hypnotics and sedatives as primary drug
Table TDI-11 part (vii). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using hallucinogens as primary drug
Table TDI-11 part (viii). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using volatile inhalants as primary drug
Table TDI-11 part (ix). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using cannabis as primary drug
Table TDI-11 part (x). New clients entering outpatient treatment: age at first use of primary drug at treatment in 2003 for those countries supplying data. Number of clients using other drugs as primary drugs
Table TDI-12. New clients entering outpatient treatment: distribution of educational level (percentage) in 2003 for countries reporting data
Table TDI-13. New clients entering outpatient treatment: distribution (percentage) of labour status in 2003 for countries supplying data
Table TDI-14. All clients entering outpatient treatment: distribution (percentage) by accommodation arrangements (persons with whom the client is living) in 2003 for countries submitting data
Table TDI-15. All clients entering outpatient treatment: living conditions in 2003 for countries supplying data
Table TDI-16. New clients entering outpatient treatment: distribution (percentage) by source of referral in 2003 for countries supplying data
Table TDI-17. Route of administration of primary drug among new outpatient clients in 2003
Table TDI-17 part (i). Route of administration of primary drug among new outpatient clients in 2003. Percentage among clients with opiates as primary drug
Table TDI-17 part (ii). Route of administration of primary drug among new outpatient clients in 2003. Percentage among clients with cocaine as primary drug
Table TDI-17 part (iii). Route of administration of primary drug among new outpatient clients in 2003. Percentage among clients with stimulants as primary drug
Table TDI-17 part (iv). Route of administration of primary drug among new outpatient clients in 2003. Percentage among clients with hypnotics and sedatives as primary drug
Table TDI-18. Frequency of use of primary drug among new outpatient clients in 2003
Table TDI-18 part (i). Frequency of use of primary drug among new outpatient clients in 2003. Percentage among clients with opiates as primary drug
Table TDI-18 part (ii). Frequency of use of primary drug among new outpatient clients in 2003. Percentage among clients with cocaine as primary drug
Table TDI-18 part (iii). Frequency of use of primary drug among new outpatient clients in 2003. Percentage among clients with stimulants as primary drug
Table TDI-18 part (iv). Frequency of use of primary drug among new outpatient clients in 2003. Percentage among clients with cannabis as primary drug
Table TDI-18 part (v). Frequency of use of primary drug among new outpatient clients in 2003. Percentage among clients with hypnotics and sedatives as primary drug
Table TDI-19. New clients entering outpatient treatment: distribution by primary drug at treatment in 2003 for those countries supplying data
Table TDI-20. All clients entering outpatient treatment: distribution by primary drug at treatment in 2003 for those countries supplying data
Table TDI-21. Unemployment rates among new clients entering outpatient treatment in 2003 and in the general population aged 15 to 74 for countries providing data
Table TDI-22. Gender ratio (ratio of males to females) among new clients entering outpatient treatment by primary drug - opiates, cannabis, cocaine, other stimulants - in 2003 for countries providing data
Table TDI-23. New clients entering outpatient treatment for primary use of amphetamines and ecstasy in 2003 for countries supplying data
Table TDI-24. New clients entering outpatient treatment - distribution of secondary drug used at treatment in 2003 for countries supplying data
Table TDI-25. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug
Table TDI-25 part (i). Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug. All clients with cannabis as primary drug: numbers reporting the stated drug as secondary
Table TDI-25 part (ii). Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug. All clients with opiates as primary drug: numbers reporting the stated drug as secondary
Table TDI-25 part (iii). Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug. All clients with cocaine as primary drug: numbers reporting the stated drug as secondary
Table TDI-25 part (iv). Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug. All clients with stimulants other than cocaine as primary drug: numbers reporting the stated drug as secondary
Table TDI-26. Polydrug use among all clients entering outpatient treatment - summary over all countries supplying data for 2003 of most frequently used secondary drugs, as percentages of primary users of cannabis, opiates, cocaine or other stimulants
Needle and syringe programmes (NSP)
Table NSP-0. Needle and syringe programmes: information sources
Table NSP-1. Number of syringe provision outlets and number of syringes (in thousands) exchanged, distributed or sold in 2003
Table NSP-2. Year of introduction of needle and syringe programmes. Types of programmes available in 2003
Table NSP-3. Number of non-pharmacy needle and syringe programmes and number of syringes exchanged, distributed or sold in 2002 and 2003
Table NSP-4. Total number of pharmacy-based needle and syringe programmes and number of syringes exchanged or distributed in 2002 and 2003
Table NSP-5. Number of syringe vending machines and number of syringes distributed or sold in 2002 and 2003
Table NSP-6. Number of syringes sold to injecting drug users at community pharmacies
Drug availability and drug markets: seizures data (SZR)
Table SZR-0. Drug seizures in 2003: numbers of seizures and total quantity
Table SZR-1. Number of cannabis seizures
Table SZR-1 part (i). Number of cannabis seizures, 1994 to 2003
Table SZR-1 part (ii). Number of cannabis seizures, 1985 to 2003
Table SZR-2. Quantities of cannabis seized
Table SZR-2 part (i). Quantities (kg) of cannabis seized, 1994 to 2003
Table SZR-2 part (ii). Quantities (kg) of cannabis seized, 1985 to 2003
Table SZR-3. Number of heroin seizures
Table SZR-3 part (i). Number of heroin seizures, 1994 to 2003
Table SZR-3 part (ii). Number of heroin seizures, 1985 to 2003
Table SZR-4. Quantities of heroin seized
Table SZR-4 part (i). Quantities (kg) of heroin seized, 1994 to 2003
Table SZR-4 part (ii). Quantities (kg) of heroin seized, 1985 to 2003
Table SZR-5. Number of cocaine seizures
Table SZR-5 part (i). Number of cocaine seizures, 1994 to 2003
Table SZR-5 part (ii). Number of cocaine seizures, 1985 to 2003
Table SZR-6. Quantities of cocaine seized
Table SZR-6 part (i). Quantities (kg) of cocaine seized, 1994 to 2003
Table SZR-6 part (ii). Quantities (kg) of cocaine seized, 1985 to 2003
Table SZR-7. Number of amphetamines seizures
Table SZR-7 part (i). Number of amphetamines seizures, 1994 to 2003
Table SZR-7 part (ii). Number of amphetamines seizures, 1985 to 2003
Table SZR-8. Quantities of amphetamines seized
Table SZR-8 part (i). Quantities (kg) of amphetamines seized,1994 to 2003
Table SZR-8 part (ii). Quantities (kg) of amphetamines seized, 1985 to 2003
Table SZR-9. Number of ecstasy seizures
Table SZR-9 part (i). Number of ecstasy seizures, 1994 to 2003
Table SZR-9 part (ii). Number of ecstasy seizures, 1987 to 2003
Table SZR-10. Quantities of ecstasy seized
Table SZR-10 part (i). Quantities (tablets) of ecstasy seized, 1994 to 2003
Table SZR-10 part (ii). Quantities (tablets) of ecstasy seized,1987 to 2003
Table SZR-11. Number of LSD seizures
Table SZR-11 part (i). Number of LSD seizures, 1994 to 2003
Table SZR-11 part (ii). Number of LSD seizures, 1985 to 2003
Table SZR-12. Quantities of LSD seized
Table SZR-12 part (i). Quantities (units) of LSD seized, 1994 to 2003
Table SZR-12 part (ii). Quantities (units) of LSD seized, 1985 to 2003
Drug availability and drug markets: prices and purity information (PPP)
Table PPP-1. Price of cannabis products at retail level, 2003
Table PPP-1 part (i). Price of cannabis products at retail level, 2003. Minimum, maximum and average price in euros
Table PPP-1 part (ii). Price of cannabis products at retail level, 2003. Sources of information
Table PPP-2. Price of heroin at retail level, 2003
Table PPP-2 part (i). Price of heroin at retail level, 2003. Minimum, maximum and average price in euros
Table PPP-2 part (ii). Price of heroin at retail level, 2003. Sources of information
Table PPP-3. Price of cocaine at retail level, 2003
Table PPP-3 part (i). Price of cocaine at retail level, 2003. Minimum, maximum and average price in euros
Table PPP-3 part (ii). Price of cocaine at retail level, 2003. Sources of information
Table PPP-4. Price of synthetic drugs at retail level, 2003
Table PPP-4 part (i). Price of synthetic drugs at retail level, 2003. Minimum, maximum and average price in euros
Table PPP-4 part (ii). Price of synthetic drugs at retail level, 2003. Sources of information
Table PPP-5. Potency of cannabis products at retail level, 2003
Table PPP-5 part (i). Potency of cannabis products at retail level, 2003. Minimum, maximum and average potency measured as percentage of tetrahydrocannabinol content
Table PPP-5 part (ii). Potency of cannabis products at retail level, 2003. Sources of information
Table PPP-5 part (iii). Potency of cannabis products at retail level, 2003. Sampling frame / type of study
Table PPP-6. Purity of heroin at retail level, 2003
Table PPP-6 part (i). Purity of heroin at retail level, 2003. Minimum, maximum and average purity (percentage)
Table PPP-6 part (ii). Purity of heroin at retail level, 2003. Sources of information
Table PPP-6 part (iii). Purity of heroin at retail level, 2003. Sampling frame / type of study
Table PPP-7. Purity of cocaine products at retail level, 2003
Table PPP-7 part (i). Purity of cocaine products at retail level, 2003. Minimum, maximum and average purity (percentage)
Table PPP-7 part (ii). Purity of cocaine products at retail level, 2003. Sources of information
Table PPP-7 part (iii). Purity of cocaine products at retail level, 2003. Sampling frame / type of study
Table PPP-8. Purity of synthetic drugs at retail level, 2003
Table PPP-8 part (i). Purity of synthetic drugs at retail level, 2003. Minimum, maximum and average purity (percentage)
Table PPP-8 part (ii). Purity of synthetic drugs at retail level, 2003. Sources of information
Table PPP-8 part (iii). Purity of synthetic drugs at retail level, 2003. Sampling frame/type of study
Graphics
General population surveys of drug use (GPS)
Figure GPS-1. Proportion of all adults (15 to 64 years old) using cannabis daily or almost daily among current users (used in the last 30 days)
Figure GPS-2. Recent use (last year) of cannabis among young adults, 15 to 34 and 15 to 24 years old age group, measured by population surveys
Figure GPS-3. Current use (last month) of cannabis among young adults (aged 15 to 24), measured by national surveys
Figure GPS-4. Trends in recent use (last year) of cannabis among young adults (aged 15 to 34), measured by national surveys
Figure GPS-5. Recent use (last year) of amphetamines among young adults, 15 to 34 and 15 to 24, measured by population surveys
Figure GPS-6. Trends in recent use (last year) of amphetamines among young adults (aged 15 to 34), measured by population surveys
Figure GPS-7. Lifetime prevalence and recent (last year) use of ecstasy among young adults at selected ages, 15 to 34 and 15 to 24, measured by population surveys
Figure GPS-8. Trends in recent use (last year) of ecstasy among young adults (aged 15 to 34), measured by population surveys
Figure GPS-9. Recent use (last year) of cocaine among all young adults and young males, measured by national surveys
Figure GPS-10. Trends in recent use (last year) of cocaine among young adults (aged 15 to 34), measured by population surveys
Figure GPS-11. Lifetime prevalence of cannabis among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-12. Last year prevalence of cannabis among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-13. Current use (last 30 days) prevalence of cannabis among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-14. Trends in recent use (last year) of cannabis among young adults (aged 15 to 24), measured by national surveys
Figure GPS-15. Lifetime prevalence of amphetamine use among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-16. Last year prevalence of amphetamines among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-17. Trends in recent use (last year) of amphetamines among young adults (aged 15 to 24) by national surveys
Figure GPS-18. Lifetime prevalence of ecstasy among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-19. Last year prevalence of ecstasy among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-20. Trends in recent use (12 month) of ecstasy among young adults (aged 15 to 24)
Figure GPS-21. Lifetime prevalence of cocaine use among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group, in some EU countries
Figure GPS-22. Last year prevalence of cocaine use among all adults (15 to 64 years old), young adults (15 to 34 years old) and for the 15 to 24 years old age group
Figure GPS-23. Recent use (last year) of amphetamines, ecstasy and cocaine among young adults
Figure GPS-23 part (i). Recent use (last year) of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34)
Figure GPS-23 part (ii). Recent use (last year) of amphetamines, ecstasy and cocaine among young adults (aged 15 to 24)
Figure GPS-24. Continuation rates of cannabis, cocaine and ecstasy
Figure GPS-24 part (i). Continuation rate of cannabis (last year prevalence as a proportion of lifetime prevalence)
Figure GPS-24 part (ii). Continuation rate of cocaine (last year prevalence as a proportion of lifetime prevalence)
Figure GPS-24 part (iii). Continuation rate of ecstasy (last year prevalence as a proportion of prevalence)
Studies of youth and the schools population (EYE)
Figure EYE-1. Cannabis prevalence rates
Figure EYE-1 part (i). Lifetime, last year and last month prevalence of cannabis use among 15 to 16 year old school students in 2003
Figure EYE-1 part (ii). Lifetime prevalence of cannabis use among 15 to 16 year-old school students reported in the 1995, 1999 and 2003 rounds of the ESPAD survey
Figure EYE-1 part (iii). Comparison of male and female school students' lifetime prevalence (percentage) of cannabis use 40 or more times among 15 to 16 year old school students in 2003
Figure EYE-1 part (iv). Comparison of 15 to 16 and 17 to 18 year old school students' current (last month) prevalence of cannabis use in 2003
Figure EYE-1 part (v). Comparison of lifetime prevalence of cannabis use with perceived great risk (percentages), among 15 to 16 year old school students in 2003
Figure EYE-1 part (vi). Comparison of lifetime prevalence for cannabis and ecstasy use with easy availability (percentages) among 15 to 16 year old school students in 2003
Figure EYE-1 part (vii). Comparison of 1999 and 2003 (percentage) of 15 to 16 year old school students who reported that they first used cannabis 13 years or younger
Figure EYE-1 part (viii). Comparison of lifetime prevalence (percentage) of cannabis use and drinking 5 or more drinks in a row during past month among 15 to 16 year old school students in 2003
Figure EYE-1 part (ix). Changes 1995 to 2003 in percentage lifetime prevalence of cannabis use among 15 to 16 year old school students
Figure EYE-2. Lifetime prevalence for drugs other than cannabis among school students
Figure EYE-2 part (i). Changes 1995 to 2003 in lifetime prevalence (percentage) of ecstasy use among 15 to 16 year old school students
Figure EYE-2 part (ii). Comparison of lifetime prevalence of ecstasy use with perceived great risk (percentages) among 15 to 16 year old school students
Figure EYE-2 part (iii). Comparison of last month prevalence of drinking 5 or more alcoholic drinks in a row with perceived great risk (percentages) among 15 to 16 year old school students in 2003
Figure EYE-2 part (iv). Comparison of lifetime prevalence of cocaine use with perceived great risk (percentages) among 15 to 16 year old school students in 2003
Figure EYE-2 part (v). Lifetime prevalence for use of ecstasy, LSD and other hallucinogens and magic mushrooms (percentages) among 15 to 16 year old school students in 2003
Figure EYE-2 part (vi). Lifetime prevalence for use of ecstasy and amphetamines (percentages) among 15 to 16 year old school students in 2003
Studies of the problematic drug use population (PDU)
Figure PDU-1. Estimates of the prevalence of problem drug use, 1999 to 2003 (rate per 1000 population aged 15 to 64)
Figure PDU-2. Estimated rate of injecting drug use, 1999 to 2003 (rate per 1000 aged 15 to 64)
Figure PDU-3. Trends in injecting drug use: percentage injecting among all heroin clients in treatment
Figure PDU-3 part (i). Trends in injecting drug use: percentage injecting among all heroin clients in treatment. Percentage IDU among all heroin clients entering treatment
Figure PDU-3 part (ii). Trends in injecting drug use: percentage injecting among all heroin clients in treatment. Percentage IDU among heroin clients entering treatment for the first time
Figure PDU-4. Estimated prevalence of and trends in problem drug use at the national level (rrate per 1000 population aged 15 to 64). Trends per country
Figure PDU-4 part (i). Estimated prevalence of and trends in problem drug use at the national level (rate per 1000 population aged 15 to 64). Trends per country: average of all estimation methods
Figure PDU-4 part (ii). Estimated prevalence of and trends in problem drug use at the national level (rate per 1000 population aged 15 to 64). Trends per country: estimated by multiplier method from treatment data
Figure PDU-4 part (iii). Estimated prevalence of and trends in problem drug use at the national level (rate per 1000 population aged 15 to 64). Trends per country: estimated by multiplier method from police data
Figure PDU-4 part (iv). Estimated prevalence of and trends in problem drug use at the national level (rate per 1000 population aged 15 to 64). Trends per country: estimated by capture recapture method
Figure PDU-4 part (v). Estimated prevalence of and trends in problem drug use at the national level (rate per 1000 population aged 15 to 64). Trends per country: extrapolation by multivariate indicator method
Figure PDU-5. Estimated prevalence of and trends in injecting drug use at the national level (rate per 1000 population aged 15 to 64)
Figure PDU-6. National and local estimates of the prevalence of problem drug use, 1999 to 2003 (rate per 1000 population aged 15 to 64)
Figure PDU-7. National and local estimates of the prevalence of injecting drug use, 1999 to 2003 (rate per 1000 population aged 15 to 64)
Drug-related infectious diseases (INF)
Figure INF-1. AIDS cases among IDUs by country (WHO European Region) and year of diagnosis (1982 to2003) adjusted for reporting delays
Figure INF-2. AIDS cases by transmission group and year of diagnosis (1987 to 2003) adjusted for reporting delays, EU
Figure INF-3. HIV prevalence among injecting drug users – studies with national and subnational coverage, 2002 to 2003
Figure INF-4. HIV prevalence among injecting drug users under age 25 – studies with national and subnational coverage, 2002 to 2003
Figure INF-5. HIV prevalence among injecting drug users (injecting less than 2 years) – studies with national and subnational coverage, 2002 to 2003
Figure INF-6. HCV prevalence among injecting drug users – studies with national and subnational coverage, 2002 to 2003
Figure INF-7. HCV prevalence among injecting drug users under age 25 – studies with national and subnational coverage, 2002 to 2003
Figure INF-8. HCV prevalence among new injecting drug users (injecting less than 2 years) – studies with national and subnational coverage, 2002 to 2003
Figure INF-9. HBV prevalence among injecting drug users (percentage with HBsAg) – studies with national and subnational coverage, 2002 to 2003
Figure INF-10. HBV (antibodies) prevalence among injecting drug users – studies with national and subnational coverage, 2002 to 2003
Figure INF-11. HIV infections newly diagnosed in injecting drug users in selected EU countries, Russia and Ukraine, by year of report
Figure INF-12. Proportion of notified cases of hepatitis C that are reported as IDU for some EU countries
Figure INF-13. Numbers of notified cases of hepatitis C in IDUs, 1992 to 2003 for some EU countries
Figure INF-14. Notified cases of hepatitis B, proportion of cases reported as IDU
Figure INF-15. Trends in numbers of notified cases of hepatitis B in IDUs, 1992 to 2003
Figure INF-16. Trends in HIV seroprevalence among injecting drug users, 1991 to 2003
Figure INF-17. Trends in HCV seroprevalence among injecting drug users, 1997 to 2004
Figure INF-18. Trends in HBV (HBsAg) seroprevalence among IDUs, 1997 to 2003
Figure INF-19. Trends in HBV antibodies seroprevalence among IDUs - trends for some EU countries, 1991 to 2004
Figure INF-20. Prevalence of HIV infection among injecting drug users, 2002 to 2003
Figure INF-21. Prevalence of HCV infection among injecting drug users, 2002 to 2003
Figure INF-22. Prevalence of HBV infection (HBsAg) among injecting drug users, 2002 to 2003
Figure INF-23. Prevalence of HBV infection (antibodies) among injecting drug users, 2002 to 2003
Figure INF-24. Clinically diagnosed AIDS incidence per 100000 population in Europe
Figure INF-25. Estimated access to highly active anti retroviral treatment (HAART) in WHO European Region, end of 2004
Figure INF-26. Trends in HIV seroprevalence among IDUs under the age of 25
Figure INF-27. Trends in HIV seroprevalence among new IDUs in some EU countries
Figure INF-28. Trends in HCV seroprevalence among IDUs under age 25, 1994 to 2003
Figure INF-29. Trends in HCV seroprevalence among new IDUs, 1994 to 2003
Drug-related deaths (DRD)
Figure DRD-1. Proportion of acute drug-related deaths that show presence of opiates in 2001 to 2003
Figure DRD-2. Proportion of acute drug-related deaths occurring under the age of 25 years in 2001
Figure DRD-3. Trends in mean age of acute drug-related deaths in some of the EU-15 Member States, 1990 to 2001/03
Figure DRD-4. Trends in mean age of acute drug-related deaths in some new Member States and candidate countries of the EU 1990 to 2002/03
Figure DRD-5. Trends in the proportion of acute drug-related deaths occuring under 25 years of age in the EU, 1990 to 2003
Figure DRD-5 part (i). Overall trend in acute drug-related deaths in the EU-15 Member States and trend in the proportion of drug-related victims under 25 years old, 1990 to 2003
Figure DRD-5 part (ii). Overall trends in acute drug-related deaths in new Member States and candidate countries and trend in proportion of victims under 25 years old, 1996 to 2003
Figure DRD-6. Indexed overall trends for males and females in acute drug-related deaths in the EU-15 member states and Norway, 1990 to 2003
Figure DRD-7. Indexed time series of acute drug-related deaths in different countries and in the EU as a whole
Figure DRD-8. Long term trend in acute drug-related deaths in the EU, 1985 to 2003
Figure DRD-9. Trends in the proportion of drug-related deaths occurring under the age of 25 years old in the new Member States and candidate countries 1990 to 2003
Demand for treatment for drug use (TDI)
Figure TDI-1. New clients asking for treatment for heroin, cocaine, cannabis, other stimulants, in 11 EU countries and Bulgaria from 1996 to 2003.
Figure TDI-1 part (i). New clients asking for treatment for heroin, cocaine, cannabis, other stimulants, in 11 EU countries and Bulgaria from 1996 to 2003. Trends as a percentage of the total number of new clients
Figure TDI-1 part (ii). New clients asking for treatment for heroin, cocaine, cannabis, other stimulatants in 11 EU countries and Bulgaria from 1996 to 2003. Trend in numbers of new clients
Figure TDI-2. Male to female ratio of new clients asking for drug treatment in some European countries and Bulgaria and Romania in 2003 (all types of treatment centres)
Figure TDI-3. Incidence of new clients treated for their drug use in 2003 per 100000 population by country
Figure TDI-4. Unemployment rates among new clients attending outpatient treatment in 2003 and in the general population aged 15 to 74 in some European countries and Bulgaria
Figure TDI-5. Proportion of all treatment clients with unstable accommodation, in some European countries in 2003
Figure TDI-6. Trend in coverage of treatment demand data from 1999 to 2003: number of new clients, all clients and units
Figure TDI-7. Age distribution by primary drug among new clients in outpatient treatment centres for those countries supplying data for 2003
Figure TDI-8. Primary drug at treatment as a percentage of all clients treated for drug problems by country, in 2003 or most recent year available
Figure TDI-9
Figure TDI-9 part (ii). Proportion of new outpatient clients injecting opiates, cocaine and stimulants in 2003. Proportion of new outpatient cocaine clients injecting cocaine by country in 2003
Figure TDI-9 part (iii). Proportion of new outpatient clients injecting opiates, cocaine and stimulants in 2003. Proportion of new outpatient stimulants clients injecting stimulants, by country in 2003
Programmes for needle and syringe provision (NSP)
Figure NSP-1. Introduction of needle and syringe programmes in 24 EU countries, Norway and Bulgaria
Supplementary downloadable tables
General population surveys of drug use (GPS)
Table GPS-14. Methodological information from nationwide surveys among the general population
Studies of youth and the schools population (EYE)
Table EYE-4. School surveys: Lifetime prevalence of psychoactive substance use among 15 to 16 years old students
Table EYE-5. School surveys: Prevalence of cannabis use among students 15 to 16 years
Table EYE-5 part (i). Lifetime prevalence (LTP), last year prevalence (LYP), and last month prevalence (LMP)
Table EYE-5 part (ii). Use patterns
Studies of problematic drug use population (PDU)
Table PDU-2. Prevalence of problem drug use at national level: trends
Table PDU-2 part (i). Trends in rates
Table PDU-2 part (ii). Trends in numbers
Table PDU-3. Prevalence of problem drug use at national level: full database
Table PDU-4. Prevalence of problem drug use at local level: full database
Table PDU-5. Prevalence of problem and injecting drug use at local level: trends
Table PDU-5 part (i). Trends in rates per 1000 of the adult population
Table PDU-5 part (ii). Trends in numbers of the adult population
Studies of drug users in prison (DUP)
Table DUP-5. Overall table showing the prevalence of drug use among prisoners in EU countries and Norway (%)
Drug-related infectious diseases (INF)
Table INF-4. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2003, (a) cases per million population and (b) number of cases
Table INF-5. Notified cases of hepatitis C infection among injecting drug users: number of IDUs and percentage of IDUs among all cases with known risk factor
Table INF-5 part (i). Notifications of IDUs with hepatitis C
Table INF-5 part (ii). Notes and comments
Table INF-6. Notified cases of hepatitis B infection among injecting drug users: number of IDUs and percentage of IDUs among all cases with known risk factor
Table INF-6 part (i). Notifications of IDUs with hepatitis B
Table INF-6 part (ii). Notes and comments
Table INF-7. Incidence of hepatitis C virus antibody among injecting drug users
Table INF-8. Prevalence of HIV infection (%) among injecting drug users in the EU
Table INF-8 part (i). Data
Table INF-8 part (ii). Notes
Table INF-9. Prevalence of HIV infection (%) among injecting drug users under age 25, in the EU
Table INF-9 part (i). Data
Table INF-9 part (ii). Notes
Table INF-10. Prevalence of HIV infection (%) among new injecting drug users (injecting less than 2 years) in the EU
Table INF-10 part (i). Data
Table INF-10 part (ii). Notes
Table INF-11. Prevalence of hepatitis C infection (%) among injecting drug users in the EU
Table INF-11 part (i). Data
Table INF-11 part (ii). Notes
Table INF-12. Prevalence of hepatitis C infection (%) among injecting drug users under age 25 in the EU
Table INF-12 part (i). Data
Table INF-12 part (ii). Notes
Table INF-13. Prevalence of hepatitis C infection (%) among new injecting drug users (injecting less than 2 years) in the EU
Table INF-13 part (i). Data
Table INF-13 part (ii). Notes
Table INF-14. Prevalence of current hepatitis B infection (% with HBsAg) among injecting drug users in the EU
Table INF-14 part (i). Data
Table INF-14 part (ii). Notes
Table INF-15. Prevalence of antibodies against hepatitis B virus (%) among injecting drug users in the EU
Table INF-15 part (i). Data
Table INF-15 part (ii). Notes
Drug-related deaths (DRD)
Table DRD-5. Methodological features of drug-related deaths reported by national Reitox focal points (based on national definitions - Reitox Standard Table 5 part 1)
Table DRD-6. Drug-related deaths: national definitions